The NEUROFAN group carries out all the phases of identifying new biomarkers and therapeutic targets in diseases of the central nervous system, such as addictive disorders or neurodegenerative diseases, as well as the preclinical validation of new compounds with therapeutic potential. Our goal is to understand the molecular mechanisms involved in drug addiction and neurodegenerative diseases or diseases that occur with neurodegeneration such as alcoholism. A common mechanism in this type of pathology is neuroinflammation, which, when it becomes chronic, aggravates neurodegenerative processes. Therefore, we have a great interest in studying the mechanisms that trigger neuroinflammation and perpetuate it. This has led us to discover new targets in neuroinflammation and to study their pharmacological modulation as a new therapeutic strategy in multiple diseases that occur with neuroinflammatory processes.